InDex Pharmaceuticals Holding AB (publ) published its interim report Q3 for January-September 2022 on November 23 2022 at 08:00 a.m. CET.

Our phase III study CONCLUDE

Have a look at InDex’s corporate presentation

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis

Proud partner of: